FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Related Articles
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Anumana Expands AI Platform from Diagnostic Solutions to the Full Continuum of Cardiovascular Care
New investment fuels growth of ECG-AI platform and development of perioperative AI capabilitiesApril 24, 2025
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the…July 22, 2025
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022